Definium Therapeutics, Inc. (formerly MindMed) (DFTX) — One day after its positive Emerge readout, Definium priced an upsized underwritten offering of 20,588,236 shares at $34.00 each for roughly $700 million in gross proceeds, up from an initially proposed $500 million.
Underwriters received an option for an additional 3,088,235 shares. Proceeds are earmarked for R&D, commercialization preparation for DT120 ODT if approved, and general corporate purposes, substantially bolstering the balance sheet ahead of a potential regulatory filing.
Source: businesswire.com
For the rest of that week's sector news, read our week in review.